Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Intellia Therapeutics (NASDAQ:NTLA) announced on October 1, 2025 inducement equity awards to six new employees under its 2024 Inducement Plan. The grants total 65,200 RSUs of common stock, vesting one‑third on Oct 1, 2026, 2027 and 2028, subject to continued service. The awards were granted outside Intellia’s stockholder‑approved plans and were approved by the compensation committee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan was adopted by the board in June 2024. No cash amounts, price terms, or pro forma share dilution metrics were included in the release.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NTLA gained 2.91%, reflecting a moderate positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $62M to the company's valuation, bringing the market cap to $2.19B at that time.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 65,200 shares of Intellia’s common stock, with one-third of such RSUs vesting on October 1, 2026, 2027 and 2028.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
jason.fredette@intelliatx.com
Media:
Matt Crenson
Ten Bridge Communications
media@intelliatx.com
mcrenson@tenbridgecommunications.com
FAQ
What did Intellia (NTLA) announce on October 1, 2025 regarding employee equity?
What is the vesting schedule for the NTLA inducement RSUs granted October 1, 2025?
Why were the NTLA awards granted outside existing equity plans?
Who approved the inducement awards for Intellia (NTLA)?
When was Intellia’s 2024 Inducement Plan adopted?
Did the press release disclose dilution or financial impact of the NTLA RSU grants?
